A cute respiratory viral infections in children: how to improve the quality of treatment

Abstract

The issues of improving the quality of treatment of children with acute respiratory infections combined with minimization of the adverse effects and reduction of polypragmasy are high on the agenda. The safety and efficacy of therapy are the key quality criteria, which allows to use complex bioregulatory drugs with antiviral, anti-inflammatory and immunomodulatory effects in the combination therapy of acute respiratory infections in children. The article presents clinical cases of effective treatment of acute respiratory infections using bioregulatory therapy. Clinical case 1: a 3-year-old child, general condition of moderate severity during initial presentation, rise of body temperature up to 38.4 ºС, catarrhal manifestations. Diagnosis: J00 – ARVI, acute nasopharyngitis. Clinical case 2: a 5-year-old child, complaints of fever up to 38.3 ºС, nasal breathing difficulty (especially at night) reported, nasal discharge, wet cough with difficulty in expectoration of sputum. Diagnosis: J00, J35.2, J35.8 – ARVI, grade 2 pharyngeal tonsil hypertrophy, adenoiditis. Clinical case 3: a 12-year-old child, complaints of fever for 3 days (temperature 38.3–38.7 ºС). General condition of moderate severity due to intoxication syndrome, hyperthermia. Complaints of sore throat that was exacerbated by eating. Pharyngoscopy showed hyperemic, enlarged, edematous palatine tonsils, yellowish overlays located in lacunae. Diagnosis: J03.9 Acute tonsillitis, unspecified? All patients were prescribed combination bioregulatory therapy with a high compliance profile, good tolerance and absence of side effects. This therapy contributed to the reduction of polypragmasy and the prevention of recurrent upper respiratory infections.